Coronary artery disease in patients with cancer: challenges and opportunities for improvement.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
22
9
2021
Statut:
ppublish
Résumé
Coronary artery disease (CAD) is a common comorbidity in patients with cancer. We review shared risk factors between the two diseases and cancer treatments that increase the risk of CAD. We also discuss outcomes and management considerations of patients with cancer who develop CAD. Several traditional and novel risk factors promote the development of both CAD and cancer. Several cancer treatments further increase the risk of CAD. The presence of cancer is associated with a higher burden of comorbidities and thrombocytopenia, which predisposes patients to higher bleeding risks. Patients with cancer who develop acute coronary syndromes are less likely to receive timely revascularization or appropriate medical therapy, despite evidence showing that receipt of these interventions is associated with substantial benefit. Accordingly, a cancer diagnosis is associated with worse outcomes in patients with CAD. The risk-benefit balance of revascularization is becoming more favorable due to the improving prognosis of many cancers and safer revascularization strategies, including shorter requirements for dual antiplatelet therapy after revascularization. Several factors increase the complexity of managing CAD in patients with cancer. A multidisciplinary approach is recommended to guide treatment decisions in this high-risk and growing patient group.
Identifiants
pubmed: 34397466
doi: 10.1097/HCO.0000000000000878
pii: 00001573-202109000-00014
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
597-608Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; [Internet]. [cited 2021 Mar 1]. doi: 10.3322/caac.21660 [Epub ahead of print].
doi: 10.3322/caac.21660
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020; 141:e139–e596.
Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. Group ESCSD. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:2768–2801.
Guha A, Dey AK, Al-Kindi S, et al. Socio-economic burden of myocardial infarction among cancer patients. Am J Cardiol 2020; 141:16–22.
Han XJ, Li JQ, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med 2019; 5:221–233.
Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020; 17:503–522.
Lau ES, Paniagua SM, Liu E, et al. Cardiovascular risk factors are associated with future cancer. JACC: CardioOncology 2021; 3:48–58.
Klooster CCvt, Ridker PM, Cook NR, et al. Prediction of lifetime and 10-year risk of cancer in individual patients with established cardiovascular disease. JACC: CardioOncology 2020; 2:400–410.
Hess CN, Roe MT, Clare RM, et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. J Am Heart Assoc 2015; 4: e001779. doi: 10.1161/JAHA.115.001779.
doi: 10.1161/JAHA.115.001779
Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2019; 40:1790–1800.
Abdel-Qadir H, Thavendiranathan P, Austin PC, et al. The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study. J Natl Cancer Inst 2019; 111:854–862.
Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet 2019; 394:1041–1054.
Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol 2016; 32:900–907.
Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133:1104–1114.
Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol 2015; 66:1378–1391.
Schraufnagel DE, Balmes JR, Cowl CT, et al. Air pollution and noncommunicable diseases: a review by the forum of international respiratory societies’ environmental committee, part 2: air pollution and organ systems. Chest 2019; 155:417–426.
Blaes A, Prizment A, Koene RJ, Konety S. Cardio-oncology related to heart failure: common risk factors between cancer and cardiovascular disease. Heart Fail Clin 2017; 13:367–380.
Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. J Urol 2020; 203:1109–1116.
Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of interleukin-1beta and reduction in atherothrombotic cardiovascular events in the CANTOS Trial. J Am Coll Cardiol 2020; 76:1660–1670.
Ridker PM, MacFadyen JG, Thuren T, et al. Group CT. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390:1833–1842.
Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015; 350:g7607.
Chen W, Wang S, Tian T, et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 2009; 17:1668–1675.
Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363:1346–1353.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA: Cancer J Clin 2010; 60:207–221.
Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med 2015; 66:297–309.
Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol 2019; 4:380–387.
Lee-Six H, Obro NF, Shepherd MS, et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 2018; 561:473–478.
Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. Nat Rev Immunol 2013; 13:376–389.
Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126:9–16.
Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med 2018; 11:e001926.
Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477–2487.
Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377:111–121.
Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017; 355:842–847.
Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014; 15:47.
Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8:191–202.
Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17:729–736.
de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795–1801.
Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28:374–378.
Zafar A, Drobni ZD, Mosarla R, et al. the incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm. JACC: CardioOncology 2021; 3:101–109.
Chong JH, Ghosh AK. Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions. Interv Cardiol 2019; 14:89–94.
Clasen SC, Ky B, O’Quinn R, et al. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol 2017; 8:970–979.
Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134:75–82.
Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016; 375:1457–1467.
Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 2018; 12:409–425.
Chen XL, Lei YH, Liu CF, et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013; 8:e66721.
Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009; 54:512–515.
Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012; 12:231.
Valent P, Hadzijusufovic E, Schernthaner GH, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015; 125:901–906.
Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30:1648–1671.
Kim TD, le Coutre P, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012; 97:883–889.
Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag 2017; 13:293–303.
Singh AP, Glennon MS, Umbarkar P, et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res 2019; 115:966–977.
Manouchehri A, Kanu E, Mauro MJ, et al. Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care. Arterioscler Thromb Vasc Biol 2020; 40:301–308.
Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol 2014; 92:71–82.
Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27:1316–1321.
Waxman AJ, Clasen S, Hwang W-T, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 2018; 4:e174519–e1174519.
Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 2019; 37:1946–1955.
Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020; 142:2299–2311.
Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71:1755–1764.
Fernandez DM, Rahman AH, Fernandez NF, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med 2019; 25:1576–1588.
Gotsman I, Grabie N, Dacosta R, et al. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Investig 2007; 117:2974–2982.
Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285:885–892.
Abdel-Qadir H, Austin PC, Lee DS, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2017; 2:88–93.
Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy? Lancet 2015; 386:1317–1319.
Abdel-Qadir H, Amir E, Fischer HD, et al. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in postmenopausal women with early stage breast cancer. Eur J Cancer 2016; 68:11–21.
Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2017; 28:487–496.
Goldvaser H, Barnes TA, Seruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2018; 110:31–39.
Khosrow-Khavar F, Filion KB, Bouganim N, et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation 2020; 141:549–559.
Maor R, Sara JDS, Wanous AA, et al. Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer. Coron Artery Dis 2018; 29:687–693.
Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7:633–643.
Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2015; 68:386–396.
Hu JR, Duncan MS, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol 2020; 40:e55–e64.
O’Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015; 33:1243–1251.
Gartrell BA, Saad F. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. Ther Adv Urol 2015; 7:194–202.
Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018; 16:e645–e653.
De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995–2005.
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377:352–360.
James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377:338–351.
Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138–148.
Cuomo JR, Javaheri SP, Sharma GK, et al. How to prevent and manage radiation-induced coronary artery disease. Heart 2018; 104:1647–1653.
da Silva R. Effects of radiotherapy in coronary artery disease. Curr Atheroscler Rep 2019; 21:50.
Desai MY, Windecker S, Lancellotti P, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel. J Am Coll Cardiol 2019; 74:905–927.
Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61:2319–2328.
Bouillon K, Haddy N, Delaloge S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol 2011; 57:445–452.
Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6:557–565.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987–998.
Bharadwaj A, Potts J, Mohamed MO, et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 2020; 41:2183–2193.
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70:926–938.
Kwok CS, Wong CW, Kontopantelis E, et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021; 42:1019–1034.
Iannaccone M, D’Ascenzo F, Vadala P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018; 7:631–638.
Yusuf SW, Daraban N, Abbasi N, et al. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012; 35:443–450.
Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol 2016; 142:471–479.
Park JY, Guo W, Al-Hijji M, et al. Acute coronary syndromes in patients with active hematologic malignancies – incidence, management, and outcomes. Int J Cardiol 2019; 275:6–12.
Wang F, Gulati R, Lennon RJ, et al. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc 2016; 91:1680–1692.
Velders MA, Boden H, Hofma SH, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 2013; 112:1867–1872.
O’Gara PT, Kushner FG, Ascheim DD, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice G.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362–e425.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64:e139–e228.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68:1082–1115.
Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer 2016; 139:1281–1288.
Mei Z, Liang M, Li L, et al. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer 2017; 140:1068–1081.
Abdel-Qadir H, Bobrowski D, Zhou L, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab- based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc 2021; 10:e018393.
Farooqi MA, Malhotra N, Mukherjee SD, et al. Statin therapy in the treatment of active cancer: a systematic review and meta-analysis of randomized controlled trials. PloS one 2018; 13:e0209486.
Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019; 140:240–261.
Pothineni NV, Shah NN, Rochlani Y, et al. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann Transl Med 2017; 5:482.
Urban P, Meredith IT, Abizaid A, et al. Investigators LF. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015; 373:2038–2047.
Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv 2017; 10:2334–2337.
Windecker S, Latib A, Kedhi E, et al. Investigators OO. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 2020; 382:1208–1218.
Kirtane AJ, Stoler R, Feldman R, et al. Primary results of the EVOLVE Short DAPT Study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent. Circ Cardiovasc Interv 2021; 14:e010144CIRCINTERVENTIONS120010144.
Landes U, Kornowski R, Bental T, et al. Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis 2017; 28:5–10.
Quintana RA, Monlezun DJ, Davogustto G, et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int J Cardiol 2020; 300:106–112.
Borovac JA, Kwok CS, Iliescu C, et al. percutaneous coronary intervention and outcomes in patients with lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis). Am J Cardiol 2019; 124:1190–1197.
Ueki Y, Vögeli B, Karagiannis A, et al. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC: CardioOncology 2019; 1:145–155.
Mohamed MO, Van Spall HGC, Kontopantelis E, et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care 2021; [Internet]. [cited 2021 Mar 1]. doi:10.1093/ehjacc/zuaa032 [Epub ahead of print].
doi: 10.1093/ehjacc/zuaa032
Iliescu CA, Grines CL, Herrmann J, et al. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 2016; 87:E202–E223.
Guha A, Dey AK, Kalra A, et al. Coronary artery bypass grafting in cancer patients: prevalence and outcomes in the United States. Mayo Clin Proc 2020; 95:1865–1876.
Mennander AA, Nielsen SJ, Huhtala H, et al. History of cancer and survival after coronary artery bypass grafting: Experiences from the SWEDEHEART registry. J Thorac Cardiovasc Surg 2020; [Internet]. [cited 2021 Mar 1]. doi: 10.1016/j.jtcvs.2020.09.043 [Epub ahead of print].
doi: 10.1016/j.jtcvs.2020.09.043
Garatti A, D’Ovidio M, Saitto G, et al. Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results. Eur J Cardiothorac Surg 2020; 58:528–536.
Liu B, Chen C, Gu C, et al. Combined coronary artery bypass graft (CABG) surgery and lung resection for lung cancer in patients more than 50 years-of-age. Med Sci Monit 2018; 24:3307–3314.
Li Z, Liu B, Ge W, et al. Effect of simultaneous surgical treatment of severe coronary artery disease and lung cancer. J Int Med Res 2019; 47:591–599.
Agha AM, Gill C, Balanescu DV, et al. Identifying hemostatic thresholds in cancer patients undergoing coronary angiography based on platelet count and thromboelastography. Front Cardiovasc Med 2020; 7:9.
Feher A, Kampaktsis PN, Parameswaran R, et al. Aspirin is associated with improved survival in severely thrombocytopenic cancer patients with acute myocardial infarction. Oncologist 2017; 22:213–221.
Iliescu C, Balanescu DV, Donisan T, et al. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol 2018; 122:1465–1470.
Raphael CE, Spoon DB, Bell MR, et al. Effect of preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention. Mayo Clin Proc 2016; 91:1035–1044.
Giza DE, Marmagkiolis K, Mouhayar E, et al. Management of CAD in patients with active cancer: the interventional cardiologists’ perspective. Curr Cardiol Rep 2017; 19:56.
Nohria A, Groarke JD. Management of acute coronary syndromes in patients with cancer: room for improvement. Eur Heart J 2019; 40:1801–1803.
Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary interventions in cancer patients. Expert Rev Cardiovasc Ther 2020; 18:25–32.
Al-Hawwas M, Tsitlakidou D, Gupta N, et al. Acute coronary syndrome management in cancer patients. Curr Oncol Rep 2018; 20:78.
Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020; 382:1395–1407.
McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J 2017; 38:3488–3492.
Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 2014; 35:1949–1956.
Howard CE, Nambi V, Jneid H, Khalid U. Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long? J Am Heart Assoc 2019; 8:e012639.
Valgimigli M, Bueno H, Byrne RA, et al. Group ESCSD, Guidelines ESCCfP, Societies ESCNC. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39:213–260.
Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med 2019; 381:2032–2042.
Bangalore S, Toklu B, Patel N, et al. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation 2018; 138:2216–2226.
Navarese EP, Kowalewski M, Kandzari D, et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014; 1:e000064.
Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS Trial. JACC Cardiovasc Interv 2016; 9:426–436.
Dunn AN, Donnellan E, Johnston DR, et al. Long-term outcomes of patients with mediastinal radiation-associated coronary artery disease undergoing coronary revascularization with percutaneous coronary intervention and coronary artery bypass grafting. Circulation 2020; 142:1399–1401.
Hillis LD, Smith PK, Anderson JL, et al. American College of Cardiology F, American Heart Association Task Force on Practice G, American Association for Thoracic S, Society of Cardiovascular A, Society of Thoracic S.2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58:e123–e210.
Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation 2013; 127:1476–1485.
Fender EA, Chandrashekar P, Liang JJ, et al. Coronary artery bypass grafting in patients treated with thoracic radiation: a case–control study. Open Heart 2018; 5:e000766.
Liang JJ, Sio TT, Slusser JP, et al. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv 2014; 7:1412–1420.
Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J 2017; 187:98–103.
Kherallah RY, Harrison D, Preventza O, et al. Transcatheter aortic valve replacement after chest radiation: a propensity-matched analysis. Int J Cardiol 2021; 329:50–55.